The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. https://idavfpq165338.sharebyblog.com/38931961/glp-3-retatrutide-a-comparative-analysis